Ionis Pharmaceuticals Forecasts Full Year 2024 Revenue Guidance Of Over $575M Versus Consensus Of $635.31M, With Adjusted Operating Loss Of Less Than $(475)M And Cash, Cash Equivalents And Short-term Investments Of Around $1.7B
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals projects its full-year 2024 revenue to exceed $575M, below the consensus estimate of $635.31M. The company anticipates an adjusted operating loss of less than $(475)M and expects to have around $1.7B in cash, cash equivalents, and short-term investments.
February 21, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ionis Pharmaceuticals forecasts its 2024 revenue to exceed $575M, below the consensus of $635.31M, with an adjusted operating loss of less than $(475)M and around $1.7B in cash and investments.
The projected revenue being below consensus estimates suggests potential underperformance compared to market expectations, which could negatively impact investor sentiment and the stock price in the short term. The anticipated operating loss and the significant cash reserves might offer some stability, but the lower revenue forecast is likely to be the dominant factor influencing the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100